Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Pediatric Low-Grade Glioma (pLGG).

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioma, Brain Stem Cancer, Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration.

Robyn Gartrell, MD, MS is a physician-scientist and pediatric oncologist who joined the faculty at Johns Hopkins University School of Medicine as Assistant Professor in January 2024. Dr. Gartrell completed her clinical pediatric hematology/oncology fellowship at New York Presbyterian / Columbia University Irving Medical Center (CUIMC), and a postdoctoral fellowship in Immunotherapy and Precision Medicine. She also completed a Master of Science in Patient Oriented Research as well as her first 5 years as faculty at CUIMC. Dr. Gartrell’s primary research focuses on combination approaches including radiation, chemotherapy, and other target agents with immunotherapy to improve response, increase survival, and decrease toxicity for children, adolescents, and young adults with cancer. Her laboratory uses advances in tumor immunology to develop more effective and more personalized therapies using multiplex platforms and immunogenomics to evaluate the tumor microenvironment and determine which pediatric tumor types, and which patients, will respond to immunotherapy. Dr. Gartrell is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Glioma, Diffuse Midline Glioma H3 K27M-Mutant, HER2 Negative Breast Cancer, and Pancreatic Ductal Adenocarcinoma.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy.

Carlos Romo, M.D., is a neuro-oncologist in Baltimore, Maryland. Dr. Romo specializes in the diagnosis and treatment of brain tumors, including glioblastoma, astrocytomas, oligodendrogliomas, neurofibromas, and schwannomas among others. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. Dr. Romo also studies treatments for patient with neurofibromatosis. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists. Dr. Romo is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma.

Jennifer Chu is a Neurologist in Columbia, Maryland. Dr. Chu is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Cervical Myelopathy, Spinal Tumor, Hemangioblastoma, Dysembryoplastic Neuroepithelial Tumors (DNET), and Deep Brain Stimulation.

Sahaja Acharya is the Director of Pediatric Radiation Oncology within the Department of Radiation Oncology and Molecular Radiation Sciences. She specializes in pediatric brain tumors, pediatric sarcomas, and adult sarcomas. She is also the Associate Director for the Radiation Oncology Residency Program. She leads the Pediatric Radiation Oncology program at the Johns Hopkins Hospital and treats patients at both Johns Hopkins Hospital and Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, pediatric malignancies, and adult sarcoma. She is the Principal Investigator on external grants from ASCO Conquer Cancer, the Department of Defense, and the Carson Leslie Foundation. She is also the Principal Investigator of phase II pediatric brain tumor clinical trials. She has been invited to participate in multiple national and international guideline committees and regularly lectures on pediatric malignancies and proton therapy. Dr. Acharya received her Bachelor's in Chemistry and Political Science from Stanford University and her medical degree from Saint Louis University. She completed radiation oncology residency at Washington University in St. Louis. Dr. Acharya is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Brain Tumor, Gliomatosis Cerebri, Glioma, and Posterior Fossa Tumor.

Sarah Mcavoy is a Radiation Oncologist in Columbia, Maryland. Dr. Mcavoy is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Metastatic Brain Tumor.

Dr. Koldobskiy is an Assistant Professor of Pediatric Oncology and Pediatric Neuro-Oncology at the Sidney Kimmel Comprehensive Cancer Center. He received his B.S. and M.S. from Yale University and M.D./Ph.D. in the Medical Scientist Training Program at Johns Hopkins, conducting his thesis research with Dr. Solomon Snyder in Pharmacology and Molecular Sciences. He completed his Pediatrics residency training at Johns Hopkins and his Pediatric Hematology and Oncology fellowship training in the joint Johns Hopkins/National Institutes of Health program. He studies epigenetic variability in childhood cancer. Dr. Koldobskiy is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Leukemia, Glioma, Teratoma of the Mediastinum, and Acute Lymphoblastic Leukemia (ALL).

Desmond Brown is a Neurosurgery specialist and a Neurologist in Glen Burnie, Maryland. Dr. Brown is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioma, Gliomatosis Cerebri, Glioblastoma, Osteotomy, and Craniectomy. Dr. Brown is currently accepting new patients.

Sama Ahsan is a Pediatric Hematologist Oncology provider in Baltimore, Maryland. Dr. Ahsan is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Diffuse Midline Glioma H3 K27M-Mutant, Embryonal Tumor with Multilayered Rosettes, Pineoblastoma, and Glioma.

Graeme Woodworth is a Neurosurgery provider in Baltimore, Maryland. Dr. Woodworth is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy. Dr. Woodworth is currently accepting new patients.

John Heiss is a Neurosurgery provider in Bethesda, Maryland. Dr. Heiss is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Chiari Malformation Type 2, Syringomyelia, Chiari Malformation, Laminectomy, and Posterior Fossa Decompression.

Kevin Camphausen is a Radiation Oncologist in Bethesda, Maryland. Dr. Camphausen is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Jignesh Tailor is a General Surgeon and a Neurosurgery provider in Baltimore, Maryland. Dr. Tailor is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Choroid Plexus Cyst, Hydrocephalus, Hydrocephalus due to Congenital Stenosis of Aqueduct of Sylvius, Rhizotomy, and Awake Craniotomy.

Paul Meltzer is a Pediatric Hematologist Oncology provider in Bethesda, Maryland. Dr. Meltzer is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Pancreaticoduodenectomy.

John Laterra is a Neurologist in Baltimore, Maryland. Dr. Laterra is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor. Dr. Laterra is currently accepting new patients.

Haroon Ahmad is a Neurologist in Baltimore, Maryland. Dr. Ahmad is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.